About CARE™

The CARE™ Faculty is recognizing its 15th year in 20/20 and plans to continue its evolving discussion on biosimilars and access to innovation with robust programming in 20/20 and beyond.

The CARE™ (Community. Academic. Research. Education.) Faculty is a group of leading specialists and allied healthcare providers from across Canada.

We develop education initiatives directed at our peers, nurses, pharmacists, patients, government and private payers.


Current Events

[Recent] Publications




CARE™ Supplement:

Multiple Myeloma

The following CARE™ Supplement highlights key trial updates and data releases in the category of MM from the 2019 American Society of Hematology (ASH) annual meeting. This CARE™ Supplement focuses on daratumumab, one of the most impactful therapies on MM management in recent years.

View Publication

CARE™ at ASH happened on December 6th, 2019. It is the largest gathering of hematologists outside of Canada. CARE™ has provided a summary report and the speaker slides presentations.

View Publication


CARE™ at ASH 2019:

Presentations & Report


CARE™ Perspectives:

More Innovation Needed in Rheumatology

Select members of the CARE™ Rheumatology Faculty used the 2019 ACR conference as an opportunity to meet and discuss the impact of, and continued support for access to innovation and biosimilar adoption, specifically from a Canadian context/perspective.

View Publication

The CARE™ ACG/UEGW 2019 Conference Report highlights key news in gastroenterology with a specific focus on inflammatory bowel disease (IBD), framed from a Canadian perspective.

View Publication


CARE™ Perspectives:



CARE™ is doing a Needs Assessment on the evolving treatment landscape and recent/anticipated therapy approvals in Diffuse Large B-cell Lymphoma (DLBCL). We would greatly appreciate if you could spare a few minutes to complete our survey:

Arm your high-risk patients with information about UTSW’s comprehensive #PancreaticCancer prevention program. #pancsm

Load More...


Forum on Complement Case Series

This 4-part series sheds light on challenges many Paroxysmal Nocturnal Hemoglobinuria (PNH) patients encounter during their disease course.